KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Expenses: 2009-2024

Historic Operating Expenses for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $727.0 million.

  • Acadia Pharmaceuticals' Operating Expenses rose 11.03% to $242.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $806.2 million, marking a year-over-year decrease of 1.32%. This contributed to the annual value of $727.0 million for FY2024, which is 9.10% down from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Operating Expenses is $727.0 million, which was down 9.10% from $799.8 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Operating Expenses high stood at $799.8 million for FY2023, and its period low was $654.6 million during FY2021.
  • For the 3-year period, Acadia Pharmaceuticals' Operating Expenses averaged around $755.9 million, with its median value being $740.8 million (2022).
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Operating Expenses increased by 24.37% in 2020, and later fell by 10.13% in 2021.
  • Over the past 5 years, Acadia Pharmaceuticals' Operating Expenses (Yearly) stood at $728.3 million in 2020, then decreased by 10.13% to $654.6 million in 2021, then increased by 13.18% to $740.8 million in 2022, then rose by 7.96% to $799.8 million in 2023, then decreased by 9.10% to $727.0 million in 2024.